Kamaya Yuki, Kato Shiori, Nakano Kazuaki, Nagaya Masaki, Nagashima Hiroshi, Aizawa Mamoru
Department of Applied Chemistry, School of Science and Technology, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki 214-8571, Kanagawa, Japan.
Meiji University International Institute for Bio-Resource Research (MUIIBR), 1-1-1 Higashimita, Tama-ku, Kawasaki 214-8571, Kanagawa, Japan.
Biomater Biosyst. 2025 Jan 26;17:100107. doi: 10.1016/j.bbiosy.2025.100107. eCollection 2025 Mar.
Calcium-phosphate cement (CPC), commonly used as a bone graft substitute, sets as hydroxyapatite (HAp) and remains in the body for extended periods. To enhance bioresorbabability, we developed a chelate-setting tricalcium β-phosphate (β-TCP) cement using inositol phosphate (IP6) surface modification. By incorporating poly(lactic-co-glycolic acid) (PLGA) particles as a pore-forming agent and calcium sulfate hemihydrate (CSH) to this CPC, we created an organic/inorganic hybrid cement combining bioresorbability with favorable material properties. In this study, varying amounts of PLGA particles were added alongside CSH, and the resulting cement's properties, cytotoxicity, and response large animals (pigs) were assessed. The cement exhibited a compressive strength of ∼ 30 MPa and set within 15 min, making it suitable for clinical use. Cytotoxicity tests using Transwell® demonstrated cell growth in all cement specimens. In a pig tibia model, the amount of PLGA particle of 5 mass%, 10 mass%, and 20 mass% were tested to optimize material resorption and bone formation, compared with commercial HAp-based CPCs. Histological evaluations showed that higher amount of PLGA particles (10 mass% and 20 mass%) led to increased material resorption but impaired bone formation. The cement containing 5 mass% PLGA particles achieved the best balance, promoting the highest rate of bone formation. Thus, 5 mass% PLGA is the optimal amount for balancing resorption and bone regeneration in β-TCP cement. This formulation is expected to serve as a fully absorbable hybrid paste-type artificial bone supporting bone remodeling cycles.
磷酸钙骨水泥（CPC）通常用作骨移植替代物，凝固后形成羟基磷灰石（HAp）并在体内长时间留存。为提高生物可吸收性，我们开发了一种使用肌醇磷酸（IP6）表面改性的螯合固化β-磷酸三钙（β-TCP）骨水泥。通过将聚乳酸-乙醇酸共聚物（PLGA）颗粒作为成孔剂和半水硫酸钙（CSH）加入到这种CPC中，我们制备了一种兼具生物可吸收性和良好材料性能的有机/无机混合骨水泥。在本研究中，将不同量的PLGA颗粒与CSH一起添加，并评估所得骨水泥的性能、细胞毒性以及对大型动物（猪）的反应。该骨水泥的抗压强度约为30 MPa，在15分钟内凝固，适合临床使用。使用Transwell®进行的细胞毒性测试表明，所有骨水泥标本中细胞均能生长。在猪胫骨模型中，测试了5质量%、10质量%和20质量%的PLGA颗粒用量，以优化材料吸收和骨形成，并与市售的基于HAp的CPC进行比较。组织学评估表明，较高量的PLGA颗粒（10质量%和20质量%）会导致材料吸收增加，但骨形成受损。含有5质量% PLGA颗粒的骨水泥达到了最佳平衡，促进了最高的骨形成速率。因此，5质量%的PLGA是在β-TCP骨水泥中平衡吸收和骨再生的最佳用量。这种配方有望作为一种完全可吸收的混合膏状人工骨，支持骨重塑周期。
